Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men |
Murray, Nigel P
(Hematology, Medicine, Faculty Medicine, University Finis Terrae)
Reyes, Eduardo (Faculty of Medicine University Diego Portales, Hospital DIPRECA) Orellana, Nelson (Hospital DIPRECA) Fuentealba, Cynthia (Hospital de Carabineros de Chile, Faculty Medicine, University Finis Terrae) Jacob, Omar (Hospital de Carabineros de Chile, Faculty Medicine, University Finis Terrae) |
1 | Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy, 1, 377-88. DOI |
2 | Brodsky AS, Fischer A, Miller DH, et al (2014). Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One, 14, 94476 |
3 | Dillioglugil O, Leibman BD, Kattan MW, et al (1997). Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50, 93 DOI |
4 | Freedland SJ, Humphreys EB, Mangold LA, et al (2005). Risk of prostate cancer specific mortality following biochemical recurrence after radical prostatectomy. JAMA, 294, 433 DOI |
5 | Goranova TE, Ohue M, Shimoharu Y, et al (2011). Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis, 28, 427-35 DOI |
6 | Hull GW, Rabanni F, Abbas F, et al (2002). Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167, 528 DOI |
7 | Messing EM, Manola J, Yao J, et al (2006). Immediate versus delayed androgen depreviation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol, 7, 472 DOI |
8 | Mitchell RE, Chang SS (2008). Current controversies in the treatment of high risk prostate cancer. Curr Opin Urol, 18, 263 DOI |
9 | Murray NP, Badinez L, Duenas R, et al (2011). Positive HER-2 expression in circulating prostate cells and micrometastasis. Resistent to androgen suppression but not DES. Ind J Urol, 27, 200-206. DOI |
10 | Murray NP, Reyes E, Orellana N, et al (2013). Secondary circulating prostate cells predict biochemical failure after radical prostatectomy and without evidence of disease. The Scientific World J; http://dx.doi.org/10.1155/2013/762064 DOI |
11 | Partin AW, Mangold LA, Lamm DM, et al (2001). Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urol, 58, 843 DOI |
12 | Porter CR, Kodama K, Gibbons RP, et al (2006). 25 year prostate cancer control and survival outcomes, a 40 year radical prostatectomy single institution series. J Urol, 176, 569 DOI |
13 | Pound CR, Partin AW, Eisenberger MA, et al (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1591 DOI |
14 | The MRC Prostate Cancer Working Party Investigators Group (1997). Immediate versus deffered treatment for advanced prostate cancer; initial results of the MRC Trial. Br J Urol, 79, 235 DOI |
15 | Walz J, Chun FK, Klein EA, et al (2009). Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol, 181, 601-8. |
16 | Zeijlemaker W, Gratama JW, Schuurhuis GJ (2014). Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom, 86, 3-14 DOI |
![]() |